193 related articles for article (PubMed ID: 28834546)
1. Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment.
Kato M; Tajima N; Shimizu T; Sugihara M; Furihata K; Harada K; Ishizuka H
J Clin Pharmacol; 2018 Jan; 58(1):57-63. PubMed ID: 28834546
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study.
Li Y; Toyama K; Nakatsu T; Ishizuka H; Wu H; Cao G; Yu J; Wang Y; Liu X; Guo B; Wu J; Yu P; Hong Z; Zhang J; Wu X
Adv Ther; 2023 Apr; 40(4):1628-1643. PubMed ID: 36790683
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
[TBL] [Abstract][Full Text] [Related]
4. Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin.
Duchin K; Senaldi G; Warren V; Marbury T; Lasseter K; Zahir H
Clin Drug Investig; 2018 Nov; 38(11):1001-1009. PubMed ID: 30171457
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial.
Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S
Medicine (Baltimore); 2020 Sep; 99(36):e21976. PubMed ID: 32899037
[TBL] [Abstract][Full Text] [Related]
6. Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study.
Baba M; Takatsuna H; Matsui N; Ohwada S
J Pain Res; 2020; 13():1811-1821. PubMed ID: 32765056
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.
Yin OQ; Merante D; Truitt K; Miller R
J Clin Pharmacol; 2016 Feb; 56(2):203-12. PubMed ID: 26138993
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain.
Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
J Diabetes Investig; 2020 May; 11(3):693-698. PubMed ID: 31722446
[TBL] [Abstract][Full Text] [Related]
9. Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
Baba M; Matsui N; Kuroha M; Wasaki Y; Ohwada S
J Diabetes Investig; 2019 Sep; 10(5):1299-1306. PubMed ID: 30672128
[TBL] [Abstract][Full Text] [Related]
10. Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study
.
Dow J; Currie A; He L; Zaidi F; Zahir H
Int J Clin Pharmacol Ther; 2018 Oct; 56(10):451-458. PubMed ID: 30049303
[TBL] [Abstract][Full Text] [Related]
11. Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.
Brown K; Mendell J; Ohwada S; Hsu C; He L; Warren V; Dishy V; Zahir H
Pharmacol Res Perspect; 2018 Oct; 6(5):e00418. PubMed ID: 30151212
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.
Tachibana M; Yamamura N; Atiee GJ; Hsu C; Warren V; He L; Dishy V; Zahir H
Br J Clin Pharmacol; 2018 Oct; 84(10):2317-2324. PubMed ID: 29920736
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
14. Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients.
Kato J; Matsui N; Kakehi Y; Murayama E; Ohwada S; Sugihara M
Pain; 2019 May; 160(5):1175-1185. PubMed ID: 30913164
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Vinik A; Rosenstock J; Sharma U; Feins K; Hsu C; Merante D;
Diabetes Care; 2014 Dec; 37(12):3253-61. PubMed ID: 25231896
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic pain.
Hutmacher MM; Frame B; Miller R; Truitt K; Merante D
J Clin Pharmacol; 2016 Jan; 56(1):67-77. PubMed ID: 26073181
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies.
Kato J; Baba M; Kuroha M; Kakehi Y; Murayama E; Wasaki Y; Ohwada S
Clin Ther; 2021 May; 43(5):822-835.e16. PubMed ID: 34059327
[TBL] [Abstract][Full Text] [Related]
18. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study.
Nikaido T; Takatsuna H; Tabata S; Shiosakai K; Nakatani T; Konno SI
Pain Ther; 2022 Dec; 11(4):1195-1214. PubMed ID: 35857196
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
Tayo B; Taylor L; Sahebkar F; Morrison G
Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
